On 26/03/2018 you told me: " We reconfirm WHA has completed successfully all requirements asked of it to gain CFDA approval which we believe will be fully granted imminently. The only factor we cannot control is the timing of the final approval. "
Today is 25/09/2018, can I please know what is the update?
Thank you for your enquiry and interest in WHA. CFDA approval is now renamed SAMR approval. We have updated the market and shareholders continually and are comfortable in the belief WHA will receive SAMR approval. What we cannot predict is the time and day it will be received.
Please watch the WHA space closely during the coming two months. There are significant matters under consideration and pending, and we will advise the market and all shareholders when and if matters conclude.
It will be an exciting time for all who follow WHA and have invested in it. Thank you again for reaching out to us.
Regards,
Peter Nesveda Corporate Affairs & International Investor Relations Wattle Health Australia Ltd (ASX: WHA)
17/71 Victoria Crescent Abbotsford Victoria 3067, Australia
This email was sent by Wattle Health Australia Ltd (ABN 77 150 759 363). You received this email because you have previously contacted us, purchased products from us, or asked to receive information and updates about our products. Our privacy policy is available on our website. You may unsubscribe by emailing [email protected]. If you have any questions about how we handle your personal information, please call us on 1300 88 79 69 (or +61 3 8399 9419 for international callers), or write to us at 17/71 Victoria Crescent, Abbotsford, Victoria 3067, Australia
WHA Price at posting:
$1.09 Sentiment: Buy Disclosure: Held
